Evaluate your project the way investors and partners will.
An independent strategic review of your biotech or medtech project, built on the Pharmaxess 5P framework.
Every project gets a 360° review. The only question is when.
Investors in due diligence. Payers at HTA. Partners before licensing. Each of them will test whether your science, your development plan and your value story fit together.
The hidden risk
Where good strategies break in silence
Each decision is taken by the right expert, for good reasons. But nobody checks that, put together, these decisions still tell one coherent story.
A convincing product positioning the clinical plan cannot actually demonstrate.
A pivotal trial that satisfies the regulator (but not the comparator or endpoints payers will ask for).
An unexpected regulatory opinion or study result that forces you to rethink Plan A.
Found late, each gap can cost a trial, a valuation or a partner.
The answer
What is the 360° Check?
An independent, multidisciplinary review of your development strategy, looking at how the pieces of your project fit together, not at one discipline at a time.
A global overview
Scientific, regulatory, nonclinical, clinical, evidence, market access and value creation, in one reading.
5 deep dives
The Pharmaxess 5P framework challenges key assumptions, reveals gaps and uncovers opportunities.
A decision-ready output
What holds, what is missing, and what to prioritise before your next milestone.
The method
The Pharmaxess 5P framework
A global view of the project, completed by five interconnected deep dives, each tested against one shared product vision.
P1
Product Positioning
Is the product vision clear enough to guide every development decision?
P2
Plan of Development
Do the regulatory, nonclinical and clinical plans form one realistic and coherent path?
P3
Payers, Patients & Practitioners
Are the people who will decide adoption built into the strategy?
P4
Pricing & Access
Will today's evidence support tomorrow's price and reimbursement?
P5
Plan B
Which alternative paths could protect (or grow) the value of the asset?
The output you get
The Pharmaxess 360° Report
Validated strategic foundations
What is already solid in your project: you can build on it.
Key gaps & uncertainties
What is missing or unclear: open questions to answer before your next milestone.
Areas requiring reinforcement
What exists but is still fragile: it needs stronger evidence or better alignment.
Strategic options & value opportunities
Alternative paths and scenarios worth a closer look to add value.
Priority actions & decision points
What to do first: the actions and decisions to take, ranked by impact and urgency.
For every stage, from discovery to late development
Key moments to run a 360° Check
Before a financing round
Walk into due diligence with a coherent, credible story.
After a financing round
You have raised funds. Where do you start?
Before a key trial decision
First-in-human, Phase II and beyond: make sure the study generates the evidence you will need later.
Before partnering or licensing
Know what a partner will scrutinise (before they do).
When the strategy needs fresh eyes
An independent view before committing the next budget.
Which one is coming up for you?
Let's talkHow it works
Seven steps, one clear 360° picture
Proposal
Approach, scope and expected outputs
Set-up
CDA, work order and kick-off meeting
Questionnaire
Structured input and existing documents
Assessment
Global review plus the 5P deep dives
Findings
Strategic findings and recommendations
Presentation
Priorities and decisions discussed with management
Next steps
Implement internally or with Pharmaxess
Your time: an estimated 2–3 hours for the questionnaire.
No extra work: only existing documents are requested.
From insight to action
You decide what comes next
Move forward on your own
Your team implements the priorities, with a clear list of actions and decision points.
Continue with Pharmaxess
Support on the priorities identified, in the way that suits your team:
- Taking the work forward directly
- Bringing in trusted specialists from our network
- Supporting your team as it implements
Clémentine Laurent, PhD
Founder, Pharmaxess Consulting
Science-to-Revenue · R&D · Value · Investment
Why Pharmaxess
“A decision made during development can have a major impact on future reimbursement.” Work with one person who has worked on each side of that equation.
Development
12+ years in biotech, PhD in Biochemistry. Worked in small biotech teams with broad, hands-on responsibilities across non-clinical, clinical and regulatory development. Headed a non-clinical department for two years, supporting a drug-device combination through BfArM review and first-in-human clearance. Contributed to clinical development strategy, overall project development and regulatory interactions, including the defence of an orphan drug programme at EMA.
Value & access
5+ years in Market Access: global pricing and reimbursement strategies, positioning, evidence-generation plans, a willingness-to-pay study, work with patient organisations and advisory boards.
Product & business
Target Product Profiles, new opportunities, alternative applications and business cases. Certified in Financing Biotech Innovation (TU Munich).